Indaptus Therapeutics Advances In Clinical Trials And Expands Intellectual Property Portfolio
$INDP
Indaptus Therapeutics, Inc. (NASDAQ:INDP), a clinical stage biotechnology company, has recently disclosed its financial outcomes for the first quarter ending March 31, 2025, alongside a comprehensive corporate update. Jeffrey Meckler, the CEO of Indaptus Therapeutics, highlighted the significant strides made in the company’s clinical and research endeavors.
The company reported research and development expenses of $2.8 million for the first quarter of 2025, a significant increase from $1.6 million in the same period the previous year. This rise is primarily attributed to the escalated costs associated with the Phase 1 clinical trial of Decoy20. Conversely, general and administrative expenses decreased to $1.8 million from $2.4 million, reflecting reduced payroll and legal costs.
The net loss for the quarter was $0.32 per share, an improvement from a loss of $0.45 per share in the first quarter of 2024. As of March 31, 2025, Indaptus Therapeutics reported having $3.9 million in cash and cash equivalents, indicating a need for additional capital to sustain operations beyond the second quarter of 2025. The company’s innovative approach combines the activation of both innate and adaptive immune cells and pathways.
A notable development is the initiation of the expansion arm of the Phase 1b/2 clinical trial for Decoy20, which is being evaluated in combination with BeOne’s PD-1 checkpoint inhibitor, Tislelizumab. This study focuses on safety, dose optimization and early indications of anti-tumor activity. Meckler also announced the conclusion of enrollment for the weekly dosing arm of Decoy20, having enrolled 32 patients across two dose levels.
In addition to clinical advancements, Indaptus Therapeutics has successfully expanded its intellectual property portfolio with new patents granted in China, Japan and Israel. It is crucial for the company’s strategic positioning in the global market for infectious disease and cancer treatment solutions.
Indaptus’ patented Decoy platform technology utilizes strains of attenuated and killed, non-pathogenic, Gram-negative bacteria. This technology has shown potential in pre-clinical studies, producing significant activity against various cancers and chronic infections like hepatitis B and HIV.
Looking ahead, Indaptus Therapeutics is focused on advancing its clinical trials, particularly the anticipated combination study of Decoy20 and Tislelizumab. The ongoing developments and strategic focus on its patented Decoy platform technology could potentially lead to groundbreaking treatments for cancer and viral infections, marking significant milestones in the company’s journey towards innovation and success in the healthcare sector.
**DISCLAIMER: THIS CONTENT IS FOR INFORMATIONAL PURPOSES ONLY AND SHOULD NOT BE INTERPRETED AS INVESTMENT ADVICE. INVESTING INVOLVES RISK, INCLUDING THE POTENTIAL LOSS OF PRINCIPAL. READERS ARE ENCOURAGED TO CONDUCT THEIR OWN RESEARCH AND CONSULT WITH A QUALIFIED FINANCIAL ADVISOR BEFORE MAKING ANY INVESTMENT DECISIONS.**